Conclusions: Our study demonstrated that EI was frequently observed in JLS patients, mainly in asymptomatic patients with linear subtype. EI occurred in JLS patients with other extracutaneous manifestations and required methotrexate therapy.
Anormalidades esofágicas na esclerodermia localizada juvenil: associação com outras manifestações extracutâneas?
Palavras-chave: Métodos: Durante 31 anos, 5.881 pacientes com doenças reumáticas foram acompanhados em nossa Divisão de Reumatologia Pediátrica. O EE foi definido pela presença de sintomas (disfagia para sólidos/líquidos, azia, regurgitação esofágica, náuseas/vômitos e epigastralgia) e confirmado com pelo menos um exame que revelou EE: radiografia contrastada com bário, endoscopia digestiva alta e pHmetria esofágica de 24 horas. 
Resultados

Introduction
Juvenile scleroderma is a rare autoimmune disease, characterized by skin inflammation and fibrosis lesions, and occurs before the age of 18. [1] [2] [3] [4] This condition comprises two major types in children and adolescents: juvenile localized scleroderma (JLS) and juvenile systemic sclerosis (JSS). 1, 5, 6 Manifestations are mainly limited to the skin and subdermal tissues in JLS patients, whereas internal organs are frequently affected in JSS patients. 1, 5 Extracutaneous manifestations have been reported in up to 25% of JLS patients and are mainly characterized by musculoskeletal involvement, particularly arthritis and tenosynovitis. 7 Esophageal involvement (EI) has been described as frequent extracutaneous manifestations in JSS. [7] [8] [9] [10] This involvement has been studied in children and adolescents with JLS, however it is usually limited to case reports or case series. [5] [6] [7] [8] [9] [10] [11] [12] To our knowledge there are no studies that evaluated solely JLS patients comparing patients with and without EI.
Therefore, the aim of this study was to assess the prevalence of EI in JLS population, and the possible associations between this gastrointestinal manifestation and demographic data, clinical features, laboratory exams, treatments and outcomes.
Methods
This was a retrospective study carried out at the Pediatric Rheumatology Unit of a tertiary University Hospital, Sao Paulo city, Brazil. For a period of 31 years , 5881 patients with pediatric rheumatic diseases were followed up in the Pediatric Rheumatology Unit. The inclusion criteria were consecutive patients with JLS diagnosis followed from 1986 to 2014. Overlap syndromes with other autoimmune diseases were systematically excluded.
Demographic data and clinical features were collected from medical charts. The clinical JLS subtypes were defined according to Padua criteria 2004, and classified in 5 subtypes: circumscribed morphea, linear scleroderma, generalized morphea, pansclerotic morphea and mixed morphea. 4 EI was defined by the presence of gastrointestinal symptoms (solid/liquid dysphagia, heartburn, esophageal regurgitation, nausea/vomiting and epigastralgia) and confirmed by at least one laboratory test abnormality: barium contrast radiography, upper gastrointestinal endoscopy and 24-h esophageal pH-monitoring. Extracutaneus manifestations related to JLS, such as calcinosis, articular, central nervous system, pulmonary, cardiac and renal involvements, and treatments were also systematically recorded. 
Statistical analysis
Results were presented as number (frequency) and median (range) or mean ± standard deviation. JLS patients were divided according to the presence or absence of EI, and categorical variables were compared using Fisher's exact test and continuous variables using Mann-Whitney U-test or t-test, as indicated. The statistical significance was set at p < 0.05.
Results
JLS was observed in 56/5881 (0.9%). EI was evidenced in 23/56 (41%) of JLS patients. EI was observed in 6/23 (26%) before one year of JLS diagnosis and 17/23 (74%) after one year of JLS diagnosis. EI was present in 16/23 (69%) before two years of JLS diagnosis and 7/23 (30%) after two years of diagnosis.
EI was diagnosed by upper gastrointestinal endoscopy in 4/23 (17%), barium contrast radiography in 20/23 (87%) and 24-h esophageal pH-monitoring in 0/1 (0%) of JLS patients. Gastroesophageal reflux diagnosis was performed by radiographic barium swallow in 16/23 (69%) of JSL patients. Fifteen of 23 EI patients with JLS (65%) were asymptomatic. Heartburn and esophageal regurgitation was only observed in 1/15 patient (previously asymptomatic) after two years of follow-up. Regarding outcomes, esophageal imaging abnormalities were revaluated in 17/23 JLS patients with EI after one year of the previous exam, and 12/17 had maintenance of esophageal imaging. None of them required surgical intervention. None of them presented esophagus stenosis, neither Barrett's esophagus nor esophageal adenocarcinoma.
Demographic data, clinical subtypes and extracutaneous manifestations in JLS patients with and without EI are shown in Table 1 . The frequency of any cumulative extracutaneous manifestations was significantly higher in JLS patients with EI compared to patients without this complication (56% vs. 24%, p = 0.024). No differences were evidenced in each extracutaneous manifestations in both groups (p > 0.05). The median age of diagnosis and disease duration were similar in both groups, as well as the frequency of circumscribed morphea, linear scleroderma, generalized morphea and mixed morphea (p > 0.05, Table 1 ).
Laboratory exams and treatments in JLS patients with and without EI are shown in Table 2 . The frequency of methotrexate use was significantly higher in JLS patients with EI compared to patients without this complication (52% vs. 12%, p = 0.002). The median of blood eosinophils was similar in both groups (p > 0.05), likewise the frequency of autoantibody profile (ANA, anti-SCL-70, RF, anticentromere, ACL IgG and IgM, anti-Ro/SSA, anti-La/SSB and anti-RNP) (p > 0.05, Table 2 ).
Skin lesion biopsy was performed in 38/56 (68%) of JLS patients and revealed lymphohistiocytic inflammatory infiltrate with fibroblasts or fibrosis in dermis substituting Results are presented in median (range) and n (%). JLS, juvenile localized scleroderma; ESR, erythrocyte sedimentation rate; ANA, antinuclear autoantibodies; CRP, C reactive protein.
adipose panicle compatible with scleroderma histology in all 38 patients.
Discussion
Our study demonstrated that EI was frequently observed at diagnosis in JLS patients. EI occurred in JLS patients with other extracutaneous manifestations and required methotrexate therapy. This gastrointestinal manifestation was observed mainly in asymptomatic patients with linear subtype. The advantage of the present study was the inclusion of a JLS population of a University Hospital using standardized definition of these localized scleroderma subtypes. 8 In addition, JLS patients followed in our service had been submitted to a periodic exams evaluation annually, which included screening for esophageal, pulmonary and heart involvements. Indeed EI was observed in one third of our JLS patients two years after diagnosis, reinforcing the relevance of this longitudinal assessment.
EI has been rarely studied in JLS patients. [5] [6] [7] [8] [9] [10] [11] [12] Guariso et al., 5 reported EI in 8/14 (57%) of JLS patients, where only three of them were asymptomatic, contrasting with our study that almost two thirds were asymptomatic. Zulian et al., 7 reported gastroesophageal reflux (preferably assessed by barium contrast radiography or 24-h intraesophageal pH monitoring) in 1.6% of JLS patients. In this study the diagnosis of gastroesophageal reflux was performed only in symptomatic patients.
Barium contrast radiography was used to exclude esophageal anatomic abnormalities, however this exam cannot differentiate between non-pathological gastroesophageal reflux and gastroesophageal reflux disease. 13 In our study none of our JLS patients were infants, suggesting that this abnormality may be related to the scleroderma, as also previously reported. 7 An international study reported extracutaneous manifestations in 22% of JLS patients, and multiple extracutaneous involvements (more than one) in 4% of these patients. In this multicenter study, the main extracutaneous manifestations were articular (47%), neurologic (17%), and gastrointestinal (6%) and respiratory (3%) involvements that were rarely reported. 7 The high frequency of extracutaneous manifestations (31/56 -55%), mainly EI, arthritis/arthralgia and interstitial pneumonitis observed in this study, may be related to the fact that our Hospital usually follows-up patients with moderate/severe chronic diseases.
Blood eosinophils count and autoantibody profile did not allow differentiating between JLS patients with and without EI. Additionally, the most frequent autoantibodies in our JLS patients with esophagus involvement was ANA, as also previously reported. 4, 5, 7, 8 The treatment of general EI, that involves gastroesophageal reflux disease and esophagitis, includes lifestyle changes, pharmacologic therapies and surgical intervention 13 and seem not to be different from systemic sclerosis in adults with EI. 14, 15 In our cohort, standard therapy was introduced for symptomatic patients with adequate response and without esophagus complications. Furthermore, recent studies reported that use of methotrexate was beneficial for JLS therapy. 4, 8 The high frequency of this immunosuppressive agent used in our JLS patients with EI may be due to the disease severity observed herein.
The main limitation of this study was the retrospective design with possible missing data, and the employment of different treatments in JLS patients throughout the years. Currently, impedance pHmetry is considered to be the gold standard for the diagnosis of gastroesophageal reflux disease. 13 However, impedance pHmetry and esophageal manometry were not performed in all of our patients, since these exams were made available at our service only recently.
In conclusion, EI was frequently observed in the first two years in JLS patients, mainly asymptomatic patients with linear scleroderma subtype. EI occurred in JLS patients with other extracutaneous manifestations and required methotrexate therapy. This study reinforces the need to screen for other organs and systems involvements in JLS patients periodically.
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